Scienture (NASDAQ:SCNX) Trading Down 0.9% – What’s Next?

Shares of Scienture Holdings, Inc. (NASDAQ:SCNX) traded down 0.9% during mid-day trading on Monday . The company traded as low as $0.35 and last traded at $0.3570. Approximately 112,787 shares changed hands during trading, a decline of 74% from the average session volume of 441,267 shares. The stock had previously closed at $0.3602.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SCNX. Wall Street Zen raised Scienture to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $1.50.

Scienture Stock Up 1.8%

The firm has a market cap of $14.48 million, a PE ratio of -0.14 and a beta of 3.29. The firm’s fifty day simple moving average is $0.39 and its two-hundred day simple moving average is $0.43.

Scienture (NASDAQ:SCNX) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.15. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.40 million.

Hedge Funds Weigh In On Scienture

A hedge fund recently bought a new stake in Scienture stock. Virtu Financial LLC acquired a new position in Scienture Holdings, Inc. (NASDAQ:SCNX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned 0.22% of Scienture as of its most recent SEC filing. Hedge funds and other institutional investors own 5.68% of the company’s stock.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.